77 related articles for article (PubMed ID: 37857502)
1. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
2. [
Zeng Z; Li L; Tao J; Liu J; Li H; Qian X; Yang Z; Zhu H
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1221-1232. PubMed ID: 38062170
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.
Chandler CS; Bell MM; Chung SK; Veach DR; Fung EK; Punzalan B; Burnes Vargas D; Patel M; Xu H; Guo HF; Santich BH; Zanzonico PB; Monette S; Nash GM; Cercek A; Jungbluth A; Pandit-Taskar N; Cheung NKV; Larson SM; Cheal SM
Mol Cancer Ther; 2022 Jan; 21(1):125-137. PubMed ID: 34667111
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
[TBL] [Abstract][Full Text] [Related]
5. Formulation of patient dose of [
Amirdhanayagam J; Guleria M; Sharma R; Kumar N; Mukherjee A; Das T
J Labelled Comp Radiopharm; 2024 Apr; 67(4):131-144. PubMed ID: 38342496
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation.
Kumar N; Sharma AK; Guleria M; Shelar SB; Chakraborty A; Rakshit S; Kolay S; Satpati D; Das T
Mol Pharm; 2024 May; 21(5):2351-2364. PubMed ID: 38477252
[TBL] [Abstract][Full Text] [Related]
7. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
8. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
[TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
10. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma.
Imlimthan S; Khng YC; Keinänen O; Zhang W; Airaksinen AJ; Kostiainen MA; Zeglis BM; Santos HA; Sarparanta M
Small; 2021 May; 17(18):e2007705. PubMed ID: 33738957
[TBL] [Abstract][Full Text] [Related]
11. Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical Experience.
Rathore Y; Lakhanpal T; Chakraborty S; Chakravarty R; Mittal BR; Irrinki RNS; Laroiya I; Kaur K; Shukla J
Clin Nucl Med; 2024 Jun; 49(6):e258-e265. PubMed ID: 38579266
[TBL] [Abstract][Full Text] [Related]
12. Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.
Reilly RM; Georgiou CJ; Brown MK; Cai Z
EJNMMI Radiopharm Chem; 2024 May; 9(1):37. PubMed ID: 38703297
[TBL] [Abstract][Full Text] [Related]
13.
Salvanou EA; Kolokithas-Ntoukas A; Prokopiou D; Theodosiou M; Efthimiadou E; Koźmiński P; Xanthopoulos S; Avgoustakis K; Bouziotis P
Molecules; 2024 Feb; 29(5):. PubMed ID: 38474542
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties.
Miranda ACC; Dos Santos SN; Fuscaldi LL; Balieiro LM; Bellini MH; Guimarães MICC; de Araújo EB
Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34198999
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy.
Gawęda W; Pruszyński M; Cędrowska E; Rodak M; Majkowska-Pilip A; Gaweł D; Bruchertseifer F; Morgenstern A; Bilewicz A
Nanomaterials (Basel); 2020 Oct; 10(10):. PubMed ID: 33092037
[TBL] [Abstract][Full Text] [Related]
16. Editorial for the Special Issue "Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design".
Aprile C; Geatti O; Canziani L; Lodola L
Curr Issues Mol Biol; 2024 Mar; 46(3):2398-2401. PubMed ID: 38534768
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
18. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
19. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
